Aetram Research India: NIFTY PHARMA Weekly Sector Outlook
Nifty Pharma Faces Fresh Supply Near Recent Highs; Strength Above 26,700 Can Rebuild Momentum, While 26,250 Guards the Lower Range - 03.10.2026
Current Market Price: 26,311.55
Market Prediction
- Nifty Pharma has slipped from its recent peak zone and is now testing an important support area near 26,250–26,300. RSI around 40 points to softer momentum, while CCI remains deeply negative. ADX near 33 shows the current directional move has strength. A sustained push above 26,700 would improve sentiment.
Upcoming Events
- USFDA approvals, inspections and regulatory observations may influence export-focused pharmaceutical companies.
- Currency movement, especially USD/INR, may affect overseas revenue translation and margin expectations.
- Quarterly earnings commentary and product-launch updates could alter sector sentiment and stock-specific performance.
Major Support and Resistance
- Support: 26,250, 26,000, 25,750
- Resistance: 26,475, 26,700, 26,825
Volume Analysis
- Recent selling has come with better participation, indicating meaningful supply around the 26,500–26,700 band. If volume expands while price holds above 26,250, accumulation may emerge; continued high activity below support would signal further distribution.
Final Take Away
- The Pharma index is undergoing a corrective phase within a broader structure that is still relatively stronger than several other sectors. The 26,250 area is pivotal, while 26,700–26,825 is the zone that must be reclaimed for momentum to improve.
Next Week Prediction
- Next week may stay range-sensitive around 26,250; stability there can support a rebound toward 26,700, while a decisive slip may open 26,000–25,750.
Scenario-Based Outlook
- Bullish Scenario: Above 26,700, price may move toward 26,825–27,100 zone.
- Bearish Scenario: Below 26,250, downside risk toward 26,000–25,750 zone.
- Neutral Scenario: Between 26,250–26,700, consolidation likely.
Disclaimer: This research report is for informational purposes only. This is not an offer to buy or sell securities. Past performance is not indicative of future results. There is no guarantee of returns. Investments in securities are subject to market risks including loss of capital. Investors should consult their financial advisor before making any investment decisions.
